Head-to-head · free

Novo Nordisk A/S vs Oric Pharmaceuticals

NVO vs ORIC — return on capital, cash generation, margins and balance sheet side by side.

NVO

1 / 2

measures where NVO leads

ORIC

1 / 2

measures where ORIC leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureNVOORIC · FY2025
Revenue——
Net income—(129.5M)
Revenue growth (yearly, multi-year)——
Free cash flow—(111.7M)
Free cash flow margin——
Net cash / (debt)——
ROIC34.2%—
Return on equity60.7%-41.3%
Gross margin81.0%—
Operating margin41.3%—
Net debt / EBITDA0.67x0.32x

Figures are as reported by each company; latest fiscal year shown.

Where Novo Nordisk A/S's cash went

Not reported yet.

Full NVO profile →

Where Oric Pharmaceuticals's cash went (FY2025)

Capital spending
$712000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full ORIC profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons